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Abstract 
Background 
Tumour budding (TB), lymphatic vessel density (LVD) and lymphatic vessel invasion (LVI) 
have shown promise as prognostic factors in colorectal cancer (CRC) but reproducibility 
using conventional histopathology is challenging. We demonstrate image analysis 
methodology to quantify the histopathological features which could permit standardisation 
across institutes and aid risk stratification of Dukes B patients. 
Methods 
Multiplexed immunofluorescence of pan-cytokeratin, D2-40 and DAPI identified epithelium, 
lymphatic vessels and all nuclei respectively in tissue sections from 50 patients diagnosed 
with Dukes A (n = 13), Dukes B (n = 29) and Dukes C (n = 8) CRC. An image analysis 
algorithm was developed and performed, on digitised images of the CRC tissue sections, to 
quantify TB, LVD, and LVI at the invasive front. 
Results 
TB (HR =5.7; 95% CI, 2.38-13.8), LVD (HR =5.1; 95% CI, 2.04-12.99) and LVI (HR =9.9; 
95% CI, 3.57-27.98) were successfully quantified through image analysis and all were shown 
to be significantly associated with poor survival, in univariate analyses. LVI (HR =6.08; 95% 
CI, 1.17-31.41) is an independent prognostic factor within the study and was correlated to 
both TB (Pearson r =0.71, p <0.0003) and LVD (Pearson r =0.69, p <0.0003). 
Conclusion 
We demonstrate methodology through image analysis which can standardise the 
quantification of TB, LVD and LVI from a single tissue section while decreasing observer 
variability. We suggest this technology is capable of stratifying a high risk Dukes B CRC 
subpopulation and we show the three histopathological features to be of prognostic 
significance. 
Keywords 
Image analysis, Lymphatic vessel density, Lymphatic vessel invasion, Tumour budding, 
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Background 
Although there exist subtypes of colorectal cancer (CRC), defined by disrupted molecular 
pathways, in clinical practice prognosis and recommendation for adjuvant therapy relies upon 
histopathological analysis of haematoxylin and eosin (H&E) stained tissue sections and the 
consequent TNM or Dukes staging of the tumour [1,2]. Surgical resection is undertaken as a 
curative procedure for Dukes A and B patients [3]. However, there is a subgroup, of 5 and 
20-30% of patients respectively, who relapse and experience poor 5 year survival rates [4]. It 
is therefore imperative to successfully identify those patients who are at high risk of disease 
recurrence and who may have been under-staged. 
A wealth of original studies, systematic and meta-analysis reviews have been published on 
the subject of lymphatic vessel invasion (LVI) [5–7], lymphatic vessel density (LVD) [8–10] 
and tumour budding (TB) [11–15] in CRC prognosis [16,17]. A number of these have 
concentrated on early stage disease and the ability to utilise histopathological features to 
predict lymph node metastasis or to stratify patients at high risk of disease recurrence and 
poor outcome [6,9,16,18–22]. Although LVI and TB have been shown to be significantly 
prognostic in most of these studies they are not, along with LVD, routinely reported in the 
clinical pathology report and are not included within the minimum core data set compiled by 
the Royal College of Pathologists [1],wherein only TB is listed as a non-core data item. There 
are a number of reasons for this; inter-observer variability [7,9,23,24], multiple quantification 
methodologies resulting in no agreed or standardised reporting system [12,14,15,25] and the 
difficulty in observing occult phenomena in routine H&E stained tissue sections [26–28]. In 
fact lymphatic vessels, unlike blood vessels, are especially difficult to observe in H&E 
stained tissue sections where they may be confused with retraction artefact. Specific stains 
are more frequently being employed [9,22,26,28–30] in order to increase reporting rate and 
decrease observer variability but there is no consensus yet on what is best. Thus the manual, 
semi-quantitative scoring employed in these studies is subjective, open to variability and time 
consuming. 
The field of digital pathology is gaining momentum and beginning to be incorporated into 
routine clinical practice with regulatory clearance for primary diagnosis, for example, most 
recently approved in Canada [31]. Several studies incorporate image analysis, for example 
the quantification of immune infiltrate in the CRC microenvironment [32,33], and 
demonstrate the advantages this methodology could bring to the clinic. Automated image 
analysis of pathological slides, with its attributes of robust high throughput, fully quantitative 
and continuous data sets, however still remains largely in the realm of research. 
Here we demonstrate methodology for the computer based quantification of LVI, LVD and 
TB at the invasive front of CRC tissue sections that could, if validated, be applied in clinical 
practice. The study utilises multiplexed immunofluorescence coupled with a novel image 
analysis algorithm to quantify the three histopathological features from a single tissue 
section. This approach allows implementation of standardised, high throughput quantification 
which could be used consistently in different institutes while minimising observer variability. 
We investigate if the quantification of the three histopathological features allows the 
stratification of Dukes B patients into high and low risk of poor outcome. Additionally we 
assess the potential for the methodology to further stratify patients with Dukes A to C CRC, 
into more precisely defined high and low risk subgroups. 
Methods 
Patients and specimens 
50 patients were selected from a prospectively collected, pan-Scotland CRC cohort of 
patients under the age of 60 for whole slide imaging (WSI). Dukes B patients were selected 
on outcome (n = 29; 16 survived follow up and 13 died of CRC during follow up) in order to 
assess the ability of the methodology to successfully stratify the subgroup as high or low risk 
of disease specific survival. Dukes A (n = 13) and Dukes C (n = 8) patients were randomly 
selected for this study from the pan-Scotland cohort. Patients underwent surgical resection 
between the years of 1996 and 2003. Ethical approval for the study was received from South 
East Scotland HSS BioResource (13/ES/0126). Tumours located from the Caecum to 
transverse colon were amalgamated into right-sided CRC (n = 17), tumours left of the splenic 
flexure to the sigmoid colon were defined as left-sided CRC (n = 16) and tumours from 
within the recto-sigmoid and rectum were defined as rectal CRC (n = 17). A total of 40% of 
the patients died specifically from CRC within the patient follow up which was up to 15 
years. Clinicopathological characteristics are summarised in Table 1. 
Table 1 Clinicopathological data with univariate and multivariable analysis for disease 
specific survival within the CRC cohort 
Clinicopathological 
parameters 
Patient 
number (n) 
Univariate Multivariable 
HR 95% CI P value HR 95% CI P value 
lower upper lower upper 
Dukes 3.34 1.61 7.01 0.001 0.33 0.08 1.36 0.12 
A 13 
B 29 
C 8 
Gender 1.77 0.73 4.31 0.26 N/A 
M 24 
F 26 
Age at diagnosis 0.99 0.92 1.05 0.773 N/A 
30s 5 
40s 27 
50s 18 
T stage 3.04 1.53 6.03 0.001 5.22 1.77 15.44 0.03 
pT1 7 
PT2 7 
pT3 27 
pT4 9 
N Stage 2.62 1.54 4.46 <0.001 1.62 0.69 3.81 0.27 
N0 40 
N1 8 
N2 1 
N3 1 
Differentiation 1.14 0.37 3.54 0.83 N/A 
Well 5 
Moderate 39 
Poor 6 
Histology 0.49 0.11 2.11 0.34 N/A 
Standard 42 
Mucinous 8 
Site 0.77 0.45 1.31 0.33 N/A 
Rectal 17 
Right side 17 
Left side 16 
Budding 5.76 2.38 13.8 0.0005 2.56 0.9 7.27 0.08 
High 13 
Medium 19 
Low 18 
LVI 9.99 3.57 27.98 0.0001 6.08 1.17 31.41 0.03 
High 13 
Medium 19 
Low 18 
LVD 5.15 2.04 12.99 0.00001 1.3 0.3 5.59 0.72 
High 18 
Medium 11 
Low 21 
N/A indicates that the parameter was not included for multivariable analysis due to insignificance in univariate 
analysis. A parameter with a hazard ratio (HR) of greater than one has an adverse effect on survival and a p 
value of less than 0.05 was considered significant (bold type). 
The tissue used in this project was residual diagnostic material stored in the NHS Lothian 
diagnostic archive and provided by the NHS Lothian NRS BioResource. 
The provison of this material and the subsequent research was conducted under the approval 
held the NHS Lothian NRS BioResource, which is a REC-approved Research Tissue Bank 
(REC approval ref: 13/ES/0126). This approval was granted by East of Scotland Research 
Ethics Service, which is part of the National Research Ethics service and NHS Health 
Research Authority. This provides the necessary ethical approval for the BioResource, and 
associated researchers to collect, store and use patient samples and associated clinical data for 
research. Moreover, this approval allows use without consent of residual samples that were 
primarily collected for diagnostic purposes and have now fulfilled this requirement. All 
samples and data must be de-identified to the researcher. Therefore, patient consent was not 
required for the use of these samples. In accordance with the approval held, all samples were 
anonymised when released by the BioResource to the research group. 
Each patient was interviewed and signed informed consent was obtained for partaking in 
research. 
Immunofluorescence 
FFPE tissue blocks were sectioned at 4 µm, dewaxed and rehydrated in preparation for 
immunofluorescence. Pressure cooker heat-induced antigen retrieval was performed with 
Tris-EDTA, pH9 buffer. Endogenous hydrogen peroxidase was blocked with 3% hydrogen 
peroxide solution. Sections were incubated in DAKO serum-free block (DAKO, X0909) to 
reduce non-specific binding of antibodies. Next, sections were incubated for 1 hour at room 
temperature with primary mouse antibody against D2-40 (Dako, M3619, 1:2000) prior to an 
overnight 4˚C incubation of primary rabbit antibody against wide spectrum cytokeratin 
(Dako, Z0622, 1:150). Both antibodies were diluted in Dako antibody diluent (Dako, S0809). 
Dual antibody visualisation was performed by incubating slides in a secondary antibody 
solution of goat anti-rabbit Alexa555 conjugated antibody (Invitrogen, A21428, 1:25) and 
Dako Envision goat-mouse HRP antibody (Dako, K4001) for 1.5 hours in the dark at room 
temperature. Cy5 Tyramide (Perkin Elmer, SAT705A001EA, 1:100) was used to incubate the 
tissue for 10 minutes at room temperature for HRP signal amplification. Finally nuclei were 
visualised through slides being counterstained and mounted by adding Prolong Gold anti-fade 
reagent containing DAPI (Invitrogen, P36931) to a coverslip. 
Image analysis 
Low resolution WSI was performed at 4x objective using an Olympus AX-51 epifluorescence 
microscope (Olympus, Pennsylvania, USA). The invasive front of each tissue section was 
visually established from the low resolution image and then captured through a series of 20x 
objective images. Post capture the monochromatic high definition image layers for the 
panCK (epithelium), D2-40 (lymphatic vessel) and DAPI (nuclei) channels were imported 
into Definiens image analysis software (Definiens AG, Munich) for image segmentation and 
classification of TB, LVI and LVD. Images were automatically segmented into the regions of 
interest (ROIs); Tumour, Stroma, Necrosis/Lumen and No tissue, after a previous supervised 
image based machine learning step utilising Definiens’ Composer Technology within Tissue 
Studio®. DAPI, panCK and D2-40 fluorescence were segmented utilising intensity and area 
thresholds and classified into Nuclei, Marker 1 and Marker 2 objects respectively. The image 
analysis workspace was then imported into Definiens Developer XD™ software for more 
sophisticated hierarchical image manipulation and object optimisation whilst negating false 
positive nuclei and objects. Stromal Marker 1 and Marker 2 objects and their co-localisation 
were then classified into tumour bud categories, lymphatic vessels and lymphatic vessel 
invasion, respectively, prior to their quantification. Tumour buds were defined as containing 
1–5 cells only [13,34]; therefore Marker 1 objects must contain 1–5 associated nuclei to be 
classified as a tumour bud. The invasive front of the smallest tissue section was captured in 
its entirety by 15 images. Therefore only 15 images from the invasive front of subsequent 
tissue sections were used to quantify the histopathological features. The 15 images containing 
the highest number of LVI events were selected and from where LVD and TB counts were 
calculated. 
Data handling and statistics 
Prior to statistical analysis TB and LVI objects, exported from the 15 images, were totalled 
while the average LVD per patient, represented as D2-40 percentage of stroma, was 
calculated from the 15 images. Post data handling, LVI, LVD and TB parameters were 
loaded into X-Tile (University of Yale) [35] software along with patient outcome information 
and optimal cut-offs for each parameter were calculated. Corrected P-values for the cut-offs 
were calculated using cross-validation within Monte Carlo simulations (n = 1000). Cut-offs, 
patient data and variables were uploaded into SPSS software for Cox-regression univariate 
and multivariable analysis. Pearson’s Correlation between the histopathological features was 
also calculated using the SPSS software and P-values for the correlation was adjusted by 
Bonferoni correction for multiple testing. TMA navigator (http://www.tmanavigator.org/) 
[36] was used to plot the Kaplan-Meier curves and the significance of the separation was 
calculated via the log-rank (Mantel-Cox) test while the P-values are false discovery rate 
(FDR) corrected using the Benjamini-Hochberg procedure to account for multiple hypothesis 
testing. 
Results 
Image analysis pipeline for the quantification of histopathological features 
(Figure 1) 
Figure 1 Image analysis pipeline for histopathological feature quantification. A) Images 
for each wavelength are acquired and digitised prior to being imported into Definiens Tissue 
Studio®. B) A Composite image is created within the software; green (panCK), red (D2-40) 
& blue (DAPI). C)1. Tissue level segmentation: Tissue is segmented prior to image based 
machine learning through Definiens Composer technology; blue (stroma), maroon (tumour), 
mustard (lumen/necrosis). C)2. Object level segmentation: PanCK (Marker 1: red) and D2-40 
(Marker 2: green) staining above set thresholds are segmented. C)3. Nucleus level 
segmentation: DAPI channel is used to segment nuclei (yellow). D) Analysis workspace is 
imported into Defineins Developer™ for hierarchical layer manipulation and false positive 
marker identification. E) Object classification and colocalisation optimisation. 1. Markers 1 
in stroma (blue) classified as tumour bud (red; 1–5 nuclei), bud with debris nucleus (light 
blue; debris nuclei associated), irrelevant marker (pink; no associated nucleus) and large bud 
(dark blue; >5 nuclei). 2. Lymphatic vessels and lumen are segmented and classified (green). 
3. Colocalisation of tumour buds and lymphatic vessels are classified (yellow; LVI), (pink; 
vessel border to LVI). F. Relevant objects are quantified and exported from the software; 
Figure 1F is representative of example data acquired from image object analysis. G. 
Prognostic results are calculated from the exported analysis data which was acquired from 
image object quantification. 
Step 1: Image import and tissue segmentation 
Images were imported into Definiens Tissue Studio® image analysis software in Tagged 
Image File Format (TIFF) using the software’s customized import feature which loads each 
of the 3 digitally captured image layers and creates a composite. The software was initially 
trained to segment the tissue into 4 distinct regions of interest by manually marking up areas 
of ‘stroma’, ‘tumour’, ‘necrosis/lumen’ and ‘no tissue’ on representative images to create a 
training set. The software’s Composer Technology® utilises image based machine learning, 
calculated from the training set, to automatically segment the ROIs on all subsequent images. 
The analysis rule set was programmed to only classify consequent objects within the stroma. 
Step 2: Object segmentation 
The algorithm next segmented the nuclei using DAPI intensity and morphometrics. PanCK 
and D2-40 fluorescence is segmented and classified as Marker 1 and Marker 2 objects 
respectively. Due to inter-patient marker fluorescence heterogeneity each tissue section was 
assessed for the intensity thresholds which would allow accurate segmentation of epithelial 
cells and lymphatic vessels. 
Step 3: Object optimisation 
After initial object segmentation has been carried out in Tissue Studio® the Definiens 
workspace is imported into the Developer XD™ software package where false nuclei and 
objects are negated dependent on area, intensity and texture. Nuclear objects which are under 
16 µm2 are re-classified as debris nuclei. Due to the phenomenon of non-specific staining at 
the edge of tissue through immunohistochemistry both positive Marker 1 and 2 objects within 
50 µm of ‘no tissue’ are classified as edge effect (Additional file 1: Figure S1). Remaining 
neighbouring Markers 1 (panCK), in the stroma ROI alone, are merged and optimised for 
accurate epithelial segmentation and are hierarchically classified as ‘irrelevant marker’ (no 
associated nuclei), ‘bud with debris nucleus’ (only debris nuclei associated with marker), 
‘tumour bud’ (1–5 associated nuclei) and ‘large bud’ (over 5 nuclei associated). 
Neighbouring Markers 2 (D2-40), in the stroma, are also merged, while the vessel lumen is 
combined with the vessel wall, resulting in objects classified as vessels. Finally the co-
localisation of tumour buds and vessels are classified as LVI. The number of all objects, their 
colocalisation and the vessel percentage of stroma (LVD) are quantified and exported to 
assess their prognostic relevance in stratifying CRC patients into high and low risk 
subpopulations. 
Clinicopathological and Cox-regression analysis 
Cut-offs were calculated from the Dukes A-C cohort for high and low sub-groups and their 
significance established by Monte Carlo simulations for LVI (cut-off = 16 LVI events across 
15 images, p <0.0001), LVD (cut-off = 0.7 vessel percentage of stroma averaged across 15 
images, p = 0.002) and TB (cut-off = 287 tumour buds across 15 images, p = 0.0001). The 
cut-offs established in this manner were then applied to stratify the Dukes B subpopulation. 
Clinicopathological data and regression analysis is summarised in Table 1. Univariate 
analysis showed TB (HR =5.7; 95% CI, 2.38-13.8), LVI (HR =9.9; 95% CI, 3.57-27.98) and 
LVD (HR =5.1; 95% CI, 2.04-12.99) to be significant predictors of survival within the 
cohort. In multivariable cox-regression analysis the predictive model was adjusted for T 
stage, N stage, Dukes stage, TB, LVI and LVD and showed that only depth of local invasion 
(T stage, HR = 5.22; 95% CI,1.77-15.44) and LVI (HR =6.08; 95% CI, 1.17-31.41) were 
independent predictors of survival. To assess if LVD and LVI were associated we performed 
Pearson’s correlation and found them to be significantly correlated (r = 0.71, p <0.0003). 
Similarly LVI and TB were also found to be significantly correlated (r = 0.69, p <0.0003) 
(Figure 2). 
Figure 2 Correlation of histopathological features. Continuous data plotted through 
Pearson’s Correlation (r value) after Bonferoni correction to assess correlation between A) 
LVI and LVD and B) LVI and TB. Significance shown by P value. 
Kaplan-Meier survival curves for tumour budding 
KM curves were plotted using TMA Navigator to assess the prognostic relevance of tumour 
budding in the Dukes A to C population as well as across the Dukes B subpopulation alone 
(Figure 3). Tumour budding was significantly prognostic for poor outcome and shorter 
disease specific survival times in both the full Dukes A-C cohort (p <0.0001) and within the 
Dukes B (p = 0.0005) subpopulation. The percentage of patients still alive at the end of the 
study and in the above cut-off subgroup (>than 287 buds) was 7.7% compared to 76% in the 
low budding subgroup for the Dukes A-C cohort and 10% compared to 73% in the Dukes B 
subpopulation. Tumour budding was also found to be significant when stratifying high and 
low risk patients in 5 year survival rates for the full Dukes A-C cohort (p < 0.0001 ) and the 
Dukes B subpopulation (p = 0.0001 ). Automated analysis allows the quick comparison of the 
size of the tumour bud to the significance of prognosis (Additional file 2: Figure S2). The 
study showed there was no difference on the proportion of patients alive after full follow up 
in above cut-off groups when quantifying TB with 1–2, 1–5 or >5 associated nuclei or when 
summing tumour buds (1–5 nuclei) and large buds (>5 associated nuclei) within the Dukes B 
subpopulation. The quantification of different size categories of tumour buds within the full 
cohort also showed low percentages of patients in all categories (Table 2). 
Figure 3 Kaplan-Meier curves for tumour budding. Kaplan-Meier curves showing full 
follow up disease specific and 5 year disease specific survival of above cut-off TB group 
(>287 buds, group 2) and below cut-off TB group (<287 buds, group 1) within the full Dukes 
A-C cohort and the Dukes B subpopulation and across disease specific survival or 5 year 
survival. Significance shown by P value calculated from mantel-cox analysis and FDR 
corrected. 
Table 2 Number of patients alive after full follow up in high cut-off groups within 
tumour bud size categories 
Patient cohort  Patients alive post follow up  
Tumour buds (1–5 
nuc) 
Small Buds (1–2 nuc) Large buds (>5nuc) Total tumour budding 
Dukes A-C cohort n = 1 (7%) n =1 (7%) n = 4 (23%) n =2 (14%) 
Dukes B subpopulation n = 1 (10%) n = 1 (10%) n = 1 (10%) n = 1 (10%) 
The proportion of patients, after the study was complete, who were alive within the high-cut 
off groups of differing sizes of tumour bud categories. Total tumour budding indicates the 
sum total of the objects within the tumour buds and large buds categories. 
Kaplan-Meier survival curves for lymphatic vessel density 
The LVD was calculated for each image, meaned across 15 images captured per patient and 
KM curves were plotted from the results (Figure 4). LVD was significantly associated with 
poor outcome and shorter disease specific survival in both Dukes A-C (p = 0.0001) cohort 
and the Dukes B subpopulation (p = 0.0001). Only 26% of patients within the Dukes A-C 
cohort and 11% within the Dukes B subpopulation, who were within the above-cut-off LVD 
(>0.7% vessel density) group, survived full follow up. All 8 Dukes C patients were within the 
high LVD subgroup. Higher LVD was also significantly associated with poor disease specific 
5 year survival times for both the full cohort (p < 0.0001) and the Dukes B subgroup (p = 
0.0003) 
Figure 4 Kaplan-Meier curves for Lymphatic vessel density. Kaplan-Meier curves 
showing full follow up disease specific and 5 year disease specific survival of above cut-off 
LVD group (>0.7% vessels of total stroma area, group 2) and below cut-off LVD group (<0.7 
vessel% of stroma area, group 1) within the full Dukes A-C cohort and the Dukes B 
subpopulation and across disease specific survival or 5 year survival. Significance shown by 
P value calculated from mantel-cox analysis and FDR corrected. 
Kaplan-Meier survival curves for lymphatic vessel invasion 
Co-localisation of tumour buds and lymphatic vessels was categorised as LVI. KM analysis 
was performed and LVI was shown to be the most significantly prognostic parameter 
associated with shorter survival times in both the Dukes A-C cohort (p <0.0001) and the 
Dukes B subpopulation (p <0.0001) (Figure 5). In fact, no patients survived full follow up 
within the above cut-off LVI group (>16 LVI events) in the Dukes B patient subpopulation 
and only 11% survived follow up within the full cohort. Similarly to the other 
histopathological features quantified, LVI was associated with poor 5 year survival times for 
the full cohort (p < 0.0001) and the Dukes B subpopulation (p < 0.0001). 
Figure 5 Kaplan-Meier curves for lymphatic vessel invasion. Kaplan-Meier curves 
showing full follow up disease specific and 5 year disease specific survival of above cut-off 
LVI group (>16 LVI events, group 2) and below cut-off LVD group (<16 LVI events, group 
1) within the full Dukes A-C cohort or the Dukes B subpopulation and across disease specific 
survival or 5 year survival. Significance shown by P value calculated from mantel-cox 
analysis and FDR corrected. 
Discussion 
We report a novel semi-automated methodology to reliably identify and quantify three 
prognostic histopathological features; LVI, LVD and TB, across the invasive front of 
colorectal carcinoma. The features are captured and exported from a single tissue section 
using the one continuous image analysis algorithm. This saves considerable resource, 
compared to serial sectioning and staining prior to manual semi-quantification of each 
histopathological feature, making the approach amenable to a time-dependent clinical setting. 
All three histopathological features were found to be significant in predicting poor outcome 
and were associated with shorter survival while LVI was found to be independently 
prognostic. This may allow further stratification of a subgroup of Dukes B patients into low 
and high risk of poor outcome. 
Ueno and Hase et al. [13,34] proposed the definition of a tumour bud as 1–5 undifferentiated 
cancer cells disseminated from the invasive edge. The majority of researchers in the field 
have adopted this cut-off for TB size, and have shown TB to be prognostically significant. 
However there is no formally agreed quantification methodology [12,15] resulting in 
variability in reporting [23]. As a result TB scoring has not been incorporated into the core 
minimal dataset and is not routinely reported in the NHS clinic [1]. TB quantification 
methodology with higher inter-observer concordance has been proposed by Horcic et al. [24] 
where TB is manually counted within 10 fields at x40 objective at the invasive front. Our 
automated methodology allows the quantification of TB at x20 objective across 15 fields 
captured at the invasive front. The 15 images used for automated TB quantification results in 
a larger sampling area than other studies have so far utilised [15]. Although sampling 
methodology for the quantification of TB differs, the definition of a tumour bud comprising 
only 1–5 cells remains a constant in the literature [15]. The image analysis algorithm 
developed for this study exports the number of nuclei associated with each tumour bud. This 
allows the researcher to quickly assess the impact which changing the TB size criterion has 
on prognosis. We show that quantifying tumour buds comprised of only 1–2 cells, tumour 
buds comprised of 1–5 cells and tumour buds larger than 5 cells are all individually 
associated with poor outcome and that the classical definition of a tumour bud is therefore a 
sound one. 
Both blood and lymphatic vessel invasion are associated with nodal metastasis and poor 
prognosis [7]. Blood and lymphatic vascular invasion are, however, under-recognised in 
H&E staining alone [26,27]. Therefore the use of specific histochemical markers, such as 
Elastica staining have been employed to highlight blood vessels and increase reporting rates 
of invasion events [26]. LVI is difficult to confidently recognise in H&E stained CRC tissue 
sections. This is due to the lack of a surrounding rim of muscle, such as is found with blood 
vessels, and confusion of lymphatic vessels with retraction artefact. This, alongside no 
standardised reporting methodology, is another contributing factor for the absence of 
lymphatic vascular based prognostic features from the minimal core data set and so standard 
practice is to not report LVI or LVD in the clinic. To overcome the problem of identifying 
LVI, studies have employed immunohistochemical staining with a D2-40 antibody which 
specifically binds to lymphatic vessel endothelial cells [22,28]. Dual staining of epithelium 
and vessels allows easier recognition and reporting of LVI events [28] within the complex 
tumour microenvironment while automated quantification adds further robustness to the data. 
LVI alone has been associated with lymph node metastasis (LNM) and poor outcome [22,29]. 
The under-recognition of LVI may be a contributing factor for the under-staging of CRC 
patients [22,27] and disease recurrence in ~30% of the Dukes B population [4,37]. Our 
methodology quantifies tumour buds invading small lymphatic vessels which we term as 
LVI. We observe that out of all the histopathological features we measured, LVI is the most 
significantly prognostic. KM analysis shows that no Dukes B patients with above cut-off LVI 
survived follow up. LVI was also the only parameter to independently be associated with an 
adverse effect on disease specific survival. Some studies have shown LVD to be prognostic 
and associated to poor outcome or LNM [8,38] however others show that no correlation 
exists [9,39]. LVD assessment is, however, not standardised and most researchers employ 
various magnifications and numbers of LVD “hot-spots” utilised to create a mean LVD while 
observer variability has been shown to be strong [9]. Bias is therefore introduced to these 
studies which can be negated by WSI and automated image analysis of the invasive front or 
entire tissue section. In the methodology, which we demonstrate here, we automatically 
segment the stroma from the tumour and by doing so we are able to calculate the LVD only 
within the stromal compartment. The methodology does not rely on the manual locating of 
LVD hot-spots; rather the quantification of LVD across 15 images taken from the invasive 
front which contained the highest LVI events is used. By adopting this LVD calculation and 
minimising sampling bias we have shown LVD to be significantly associated to poor 
outcome (p = 0.0001). All Dukes C patients had a high category of LVD which suggests that 
lymphangiogenesis may occur as the disease progresses. 
It is unknown whether lymphangiogenesis occurs due to a host reaction attacking the tumour 
or by tumour cell signalling, however we show that LVI is correlated to LVD (r = 0.71, p < 
0.0003) which is in accord with separate studies [40,41]. We also observed that LVI is 
associated with TB (<0.0003), as did Ohtsuki et al. [28]. TBs could be suggested to be a more 
invasive subpopulation of cells disseminated from the tumour mass and if so may have 
acquired the ability to invade the lymphatic system and metastasise to distant nodes. 
The automatic quantification of prognostic histopathological features lends further proof to 
the value of reporting TB, LVI and LVD to stratify high risk CRC patients. The methodology 
is amenable to standardisation between institutions allowing consistent reporting of CRC. 
TB, LVI and LVD were all more significantly associated with poor outcome than Dukes 
staging, when performing univariate regression analysis, within this proof of methodology 
study. The image analysis quantification methodology of these three histopathological 
features, upon further validation in large and disparate cohorts, may become more widely 
accepted as standardised prognostic factors amenable to being incorporated into the minimal 
core data set and TNM staging. 
The ability to quantify prognostically relevant histopathological features, in a robust and 
routine manner through automated image analysis, will not only standardise the practice and 
negate observer variability but will free up a pathologist’s valuable time. We believe that as 
digital pathology becomes more common place within the clinic, automated quantification of 
histopathological features, as demonstrated here, will become an invaluable tool in the 
pathologist’s repertoire to stratify high risk cancer patients. 
Conclusion 
In conclusion, we demonstrate a computer based image analysis methodology to quantify 
tumour buds, lymphatic vessel density and lymphatic vessel invasion in immunofluorescently 
labelled colorectal cancer tissue sections. This methodology has the means to standardise the 
quantification of the three histopathological features in a robust fashion. We applied the 
methodology to a colorectal cancer cohort consisting of patients spanning Dukes A –C 
diagnoses and found all the histopathological features to be significantly relevant to 
prognosis. Lymphatic vessel invasion, in our study, was shown to be an independent 
predictor of survival. 
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Additional file 1: Figure S1 Classification of false nuclei and objects. Original composite 
images are pseudocoloured blue (DAPI), green (panCK) and red (D2-40). Images for the 
DAPI channel alone are greyscale. A)1. False nuclei are classified and negated as are nuclear 
debris. To negate a false nuclei count, post-segmentation, in the stroma or within tumour 
buds, nuclei under 16 µm2 are classified as debris nuclei. A white arrow shows a small 
section from a stromal nucleus being segmented by the tumour bud and classified as debris 
nucleus. A high background intensity of DAPI, increased by a segmented section of a stromal 
nucleus within the tumour bud, has created a false nucleus (pink). This is classified as such 
and negated. A)2. The tissue section in the example has high auto-fluorescence within the 
DAPI channel, the false nuclei segmented as a result of this are classified as such (pink). A)3. 
High DAPI channel auto-fluorescence of goblet cells within colonic crypts result in false 
nuclei segmentation, these are too classified as such (pink). B) Auto-fluorescence of muscle 
cells, within the Cy3 channel, may lead to their segmentation as panCk positive epithelial 
cells. Intensity and texture parameters are utilised to classify the falsely segmented objects as 
‘non-specific CK’. C) Non-specific staining of both panCk and D2-40 antibodies occurs close 
to the edge of tissue. All positively segmented objects which are 50 µm from ‘no tissue’ 
(green) are classified as ‘edge effect’ (blue). 
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Additional file 2: Figure S2 Kaplan-Meier plots comparing prognostic significance of 
quantifying differing sizes of tumour bud. A) Kaplan-Meier curve showing disease specific 
survival times for below cut-off (group 1) and above cut-off (group 2) in tumour buds with 1–
5 nuclei associated. B) Kaplan-Meier curve showing disease specific survival times for below 
cut-off (group 1) and above cut-off (group 2)in tumour buds with 1–2 nuclei associated. C) 
Kaplan-Meier curve showing disease specific survival times for below cut-off (group 1) and 
above cut-off (group 2) in tumour buds with greater than 5 nuclei associated. D) Kaplan-
Meier curve showing disease specific survival times for below cut-off (group 1) and above 
cut-off (group 2) upon the summing of tumour buds with 1–5 nuclei and tumour buds with 
greater than 5 nuclei. 
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